Veronika Hrubá

1.1k total citations
37 papers, 768 citations indexed

About

Veronika Hrubá is a scholar working on Genetics, Immunology and Epidemiology. According to data from OpenAlex, Veronika Hrubá has authored 37 papers receiving a total of 768 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Genetics, 19 papers in Immunology and 13 papers in Epidemiology. Recurrent topics in Veronika Hrubá's work include Inflammatory Bowel Disease (21 papers), Microscopic Colitis (13 papers) and Biosimilars and Bioanalytical Methods (11 papers). Veronika Hrubá is often cited by papers focused on Inflammatory Bowel Disease (21 papers), Microscopic Colitis (13 papers) and Biosimilars and Bioanalytical Methods (11 papers). Veronika Hrubá collaborates with scholars based in Czechia, Poland and United States. Veronika Hrubá's co-authors include Anna Maria Langkilde, Shamik Parikh, Kun‐Ho Yoon, Krzysztof Strojek, M. Elze, Dana Ďuricová, Naděžda Machková, Milan Lukáš, Karin Malíčková and Martin Bortlík and has published in prestigious journals such as Gastroenterology, Inflammatory Bowel Diseases and Diabetes Obesity and Metabolism.

In The Last Decade

Veronika Hrubá

32 papers receiving 755 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Veronika Hrubá Czechia 11 444 268 256 213 159 37 768
A. C. Tarn United Kingdom 14 367 0.8× 358 1.3× 109 0.4× 93 0.4× 401 2.5× 26 752
A. Wiland United States 10 77 0.2× 347 1.3× 41 0.2× 30 0.1× 109 0.7× 20 698
Nicole J. Krumrei United States 8 62 0.1× 92 0.3× 57 0.2× 199 0.9× 44 0.3× 12 527
Gunter Flemming Germany 11 86 0.2× 155 0.6× 44 0.2× 31 0.1× 83 0.5× 22 487
Meghan N. Feldpausch United States 13 212 0.5× 114 0.4× 90 0.4× 21 0.1× 59 0.4× 30 599
Adrian J. Santiago Ortiz United States 8 162 0.4× 70 0.3× 99 0.4× 52 0.2× 18 0.1× 11 413
Groth Cg Sweden 12 56 0.1× 452 1.7× 77 0.3× 32 0.2× 140 0.9× 72 657
Michael A. Mederos United States 9 51 0.1× 608 2.3× 61 0.2× 46 0.2× 39 0.2× 23 726
Murat Çalapkulu Türkiye 11 211 0.5× 68 0.3× 60 0.2× 26 0.1× 22 0.1× 47 317
A. Jeppsson Sweden 13 101 0.2× 141 0.5× 166 0.6× 9 0.0× 26 0.2× 21 471

Countries citing papers authored by Veronika Hrubá

Since Specialization
Citations

This map shows the geographic impact of Veronika Hrubá's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veronika Hrubá with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veronika Hrubá more than expected).

Fields of papers citing papers by Veronika Hrubá

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Veronika Hrubá. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veronika Hrubá. The network helps show where Veronika Hrubá may publish in the future.

Co-authorship network of co-authors of Veronika Hrubá

This figure shows the co-authorship network connecting the top 25 collaborators of Veronika Hrubá. A scholar is included among the top collaborators of Veronika Hrubá based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Veronika Hrubá. Veronika Hrubá is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ďuricová, Dana, Martin Kolář, Naděžda Machková, et al.. (2023). Subcutaneous Infliximab in Refractory Crohn’s Disease Patients: A Possible Biobetter?. Crohn s & Colitis 360. 5(4). otad040–otad040. 10 indexed citations
2.
Lukáš, Milan, Veronika Hrubá, Naděžda Machková, et al.. (2023). Switch from biosimilar infliximab CT-P13 to biosimilar infliximab SB-2 in the long-term maintenance therapy in IBD patients – prospective observational study. 77(4). 336–341. 1 indexed citations
3.
Kolář, Martin, et al.. (2023). EFFICIENCY OF DUAL THERAPY WITH VEDOLIZUMAB AND TOFACITINIB IN REFRACTORY ULCERATIVE COLITIS PATIENTS – SINGLE CENTRE EXPERIENCE. Inflammatory Bowel Diseases. 29(Supplement_1). S78–S78.
4.
Lukáš, Milan, et al.. (2023). SUBCUTANEOUS INFLIXIMAB IN REFRACTORY CROHN'S DISEASE PATIENTS AFTER THE MULTIPLE TREATMENT FAILURES - SHORT TREATMENT OUTCOMES. Inflammatory Bowel Diseases. 29(Supplement_1). S76–S76.
5.
Ďuricová, Dana, et al.. (2023). P408 Dual therapy with vedolizumab and tofacitinib in refractory ulcerative colitis patients – single centre experience. Journal of Crohn s and Colitis. 17(Supplement_1). i538–i538. 1 indexed citations
6.
Ďuricová, Dana, Martin Lukáš, Naděžda Machková, et al.. (2022). Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients. Journal of Crohn s and Colitis. 16(9). 1347–1353. 8 indexed citations
7.
Malíčková, Karin, Martin Bortlík, Dana Ďuricová, et al.. (2020). Telemedicine and inflammatory bowel disease – results of the IBD Assistant pilot project. 74(1). 18–27. 1 indexed citations
8.
Malíčková, Karin, Martin Bortlík, Dana Ďuricová, et al.. (2020). P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project. Journal of Crohn s and Colitis. 14(Supplement_1). S352–S353. 2 indexed citations
9.
Lukáš, Martin, Karin Malíčková, Martin Bortlík, et al.. (2020). Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre. Journal of Crohn s and Colitis. 14(7). 915–919. 42 indexed citations
10.
Kolář, Martin, Dana Ďuricová, Martin Bortlík, et al.. (2019). Vedolizumab vs. ustekinumab as second-line therapy in Crohn’s disease in clinical practice. 73(1). 25–31. 3 indexed citations
11.
Ďuricová, Dana, Eva Dvořáková, Ondřej Hradský, et al.. (2018). Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation. Inflammatory Bowel Diseases. 25(4). 789–796. 61 indexed citations
12.
Ďuricová, Dana, et al.. (2018). P614 Pregnancy outcomes in women with IBD treated with biosimilar infliximab. Journal of Crohn s and Colitis. 12(supplement_1). S419–S420. 7 indexed citations
13.
Bortlík, Martin, Naděžda Machková, Veronika Hrubá, et al.. (2018). Efficacy of ustekinumab in a patient refractory to other biological treatment. 72(1). 47–49.
14.
Ďuricová, Dana, Eva Dvořáková, Ondřej Hradský, et al.. (2018). Vliv expozice anti-TNF-alfa in utero na vývoj imunitního systému exponovaných dětí – kontrolovaná multicentrická studie. 72(6). 479–485.
15.
Ďuricová, Dana, Martin Bortlík, Veronika Hrubá, et al.. (2017). Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre. Digestive Diseases. 35(1-2). 91–100. 41 indexed citations
16.
Kolář, Martin, Dana Ďuricová, Martin Bortlík, et al.. (2016). Biosimilar infliximab in anti-TNF-naïve IBD patients – 1-year clinical follow-up. 70(6). 514–522. 1 indexed citations
17.
Bortlík, Martin, Dana Ďuricová, Naděžda Machková, et al.. (2015). Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. Scandinavian Journal of Gastroenterology. 51(2). 196–202. 39 indexed citations
18.
Malíčková, Karin, Dana Ďuricová, Martin Bortlík, et al.. (2015). Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease. Biologicals. 44(1). 33–36. 25 indexed citations
19.
Schumm‐Draeger, P.‐M., et al.. (2014). Twice‐daily dapagliflozin co‐administered with metformin in type 2 diabetes: a 16‐week randomized, placebo‐controlled clinical trial. Diabetes Obesity and Metabolism. 17(1). 42–51. 51 indexed citations
20.
Strojek, Krzysztof, Kun‐Ho Yoon, Veronika Hrubá, et al.. (2011). Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial. Diabetes Obesity and Metabolism. 13(10). 928–938. 344 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. C. Tarn Breakdown of academic impact, for papers by A. Wiland Breakdown of academic impact, for papers by Nicole J. Krumrei Breakdown of academic impact, for papers by Gunter Flemming Breakdown of academic impact, for papers by Meghan N. Feldpausch Breakdown of academic impact, for papers by Adrian J. Santiago Ortiz Breakdown of academic impact, for papers by Groth Cg Breakdown of academic impact, for papers by Michael A. Mederos Breakdown of academic impact, for papers by Murat Çalapkulu Breakdown of academic impact, for papers by A. Jeppsson
Rankless by CCL
2026